RAPPRapport Therapeutics Inc. Common Stock
48.24USD-1.69%Mkt Cap: 2.31B $P/E: —3d ago
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous sy…